Sandoz Group AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1986-01-01
- Employees
- 20K
- Market Cap
- $19B
- Website
- http://www.sandoz.com
To Demonstrate the Relative Bioavailability Study of Promethazine HCl 50 mg Tablets Under Fasting Conditions
Phase 1
Completed
- Conditions
- Allergy
- Interventions
- First Posted Date
- 2009-07-27
- Last Posted Date
- 2017-03-28
- Lead Sponsor
- Sandoz
- Target Recruit Count
- 36
- Registration Number
- NCT00947063
To Demonstrate the Relative Bioavailability Study of Ondansetron HCl 24 mg Tablets Under Non-Fasting Conditions
Phase 1
Completed
- Conditions
- NauseaVomiting
- Interventions
- First Posted Date
- 2009-07-27
- Last Posted Date
- 2017-03-28
- Lead Sponsor
- Sandoz
- Target Recruit Count
- 26
- Registration Number
- NCT00947128
To Demonstrate the Effect of Food on the Bioavailability of Glipizide
Phase 1
Completed
- Conditions
- Type 2 Diabetes
- Interventions
- Drug: 10 mg Glipizide Tablet (Geneva Pharmaceutical, Inc.), Administered Immediately After a Standard Breakfast.Drug: 10 mg Glucotrol Tablet (Roerig), Administered Immediately After a Standard Breakfast.Drug: 10 mg Glipizide Tablet (Geneva Pharmaceutical, Inc.), Administered After an Overnight Fast.
- First Posted Date
- 2009-07-27
- Last Posted Date
- 2017-03-28
- Lead Sponsor
- Sandoz
- Target Recruit Count
- 18
- Registration Number
- NCT00947024
To Demonstrate the Relative Bioavailability Study of Ondansetron HCl 24 mg Tablets Under Fasting Conditions
Phase 1
Completed
- Conditions
- NauseaVomiting
- Interventions
- First Posted Date
- 2009-07-27
- Last Posted Date
- 2017-03-28
- Lead Sponsor
- Sandoz
- Target Recruit Count
- 26
- Registration Number
- NCT00946387
To Demonstrate the Relative Bioavailability of Sandoz Inc. and UCB Pharma, Inc (Keppra) 750 mg Levetiracetam Tablets In Healthy Adults Volunteers Under Fasting Conditions
Phase 1
Completed
- Conditions
- Seizure
- Interventions
- First Posted Date
- 2009-07-27
- Last Posted Date
- 2017-03-28
- Lead Sponsor
- Sandoz
- Target Recruit Count
- 20
- Registration Number
- NCT00946751
To Demonstrate the Relative Bioavailability of Hydroxychloroquine Sulfate, 200 mg Tablets
Phase 1
Completed
- Conditions
- ImmunosuppressionRheumatism
- Interventions
- First Posted Date
- 2009-07-27
- Last Posted Date
- 2017-03-28
- Lead Sponsor
- Sandoz
- Target Recruit Count
- 72
- Registration Number
- NCT00946790
To Demonstrate the Relative Bioavailability, Parallel Study Of Leflunomide 20 mg Tablets Under Fasting Conditions
Phase 1
Completed
- Conditions
- Rheumatoid ArthritisPsoriatic Arthritis
- Interventions
- First Posted Date
- 2009-07-27
- Last Posted Date
- 2017-03-28
- Lead Sponsor
- Sandoz
- Target Recruit Count
- 52
- Registration Number
- NCT00946686
To Demonstrate the Relative Bioavailability of Fluoxetine Hydrochloride Capsules, 40 mg
Phase 1
Completed
- Conditions
- Depression
- Interventions
- First Posted Date
- 2009-07-27
- Last Posted Date
- 2017-03-28
- Lead Sponsor
- Sandoz
- Target Recruit Count
- 30
- Registration Number
- NCT00947076
To Demonstrate the Relative Bioavailability Study of Ramipril 10 mg Capsules Under Non-Fasting Conditions
Phase 1
Completed
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2009-07-27
- Last Posted Date
- 2017-03-28
- Lead Sponsor
- Sandoz
- Target Recruit Count
- 48
- Registration Number
- NCT00946621
To Demonstrate the Relative Bioavailability of Sandoz Inc. and Tyco Healthcare (Tofranil) 50 mg Imipramine Hydrochloride Tablets In Healthy Adults Volunteers Under Fasting Conditions
Phase 1
Completed
- Conditions
- Depression
- Interventions
- First Posted Date
- 2009-07-27
- Last Posted Date
- 2017-03-28
- Lead Sponsor
- Sandoz
- Target Recruit Count
- 48
- Registration Number
- NCT00946764
© Copyright 2025. All Rights Reserved by MedPath